Laboratory Monitoring for Clozapine (Clozeril)
Patients on clozapine require absolute neutrophil count (ANC) monitoring weekly for the first 18 weeks, then every 4 weeks until 2 years, after which routine ANC monitoring can be discontinued but annual complete blood counts should continue for haematological malignancy screening. 1
Primary Hematologic Monitoring
ANC Monitoring Schedule
The 2026 global consensus guidelines from The Lancet Psychiatry provide the most current evidence-based monitoring protocol 1:
- Weeks 1-18: Weekly ANC testing
- Weeks 19 through 2 years: Every 4 weeks
- After 2 years: Discontinue routine ANC monitoring
- Lifelong: Annual complete blood count for haematological malignancy screening
Critical ANC Thresholds
Before starting clozapine, the FDA label requires 2:
- ANC ≥2000/mm³
- WBC ≥3500/mm³
During treatment, consider clozapine cessation if 1:
- ANC <1.0×10⁹ cells/L (general population)
- ANC <0.5×10⁹ cells/L (patients with benign ethnic neutropenia or DARC/ACKR1-null status)
Important caveat: After 2 years of treatment, strongly consider alternative causes before stopping clozapine for low ANC, as the risk of clozapine-induced agranulocytosis declines substantially over time 1.
Metabolic Monitoring
Blood Tests for Metabolic Syndrome
Every 6-12 months 1:
- HbA1c
- Fasting blood glucose
- Triglycerides
- HDL cholesterol
Biometric Measurements
Every 3 months 1:
- Blood pressure (lying and standing)
- Heart rate
- Waist circumference
- Weight
Clozapine Level Monitoring
Where available, check clozapine serum levels 1:
- Annually
- With smoking pattern changes
- During infection/inflammatory illness (e.g., pneumonia)
- With mental state changes
- With ADR changes (myoclonus, increased sedation)
- When CYP1A2 inhibiting medications are added or stopped
Cardiac Monitoring
- ECGs should be considered annually (though this did not reach consensus threshold of 75% agreement) 1
- Echocardiograms only if clinically indicated (not routinely) 1
Adverse Drug Reaction Monitoring
For the first 2 years, monitor ADRs at each ANC testing appointment. After 2 years, when ANC monitoring stops, screen for ADRs every 3 months 1.
ADR Checklist includes:
- Metabolic syndrome
- Constipation and gastrointestinal hypomotility (potentially lethal)
- Gastro-oesophageal reflux
- Sialorrhea, drooling, choking
- Sedation
- Nocturnal enuresis and urinary incontinence
- Dizziness and orthostatic hypotension
- Tachycardia
- Sleep apnoea
- Seizures and myoclonus
- Obsessive-compulsive symptoms
- Pneumonia
- Sexual dysfunction
- Heart failure
Key Clinical Pitfalls
Real-world adherence is suboptimal: A 2026 US study found only 71% of patients had pre-initiation testing, and testing rates during the first 6 months averaged 2.2 tests per 30 days (lower than the weekly requirement) 3. This underscores the need for systematic monitoring protocols.
Immediate action required: Patients must be instructed to report fever, weakness, lethargy, or sore throat immediately, as these may indicate agranulocytosis 2. This is critical for patients who may not be able to articulate symptoms 4.
Shared-care model recommended: After 2 years on clozapine, patients should see primary care for ADR screening every 3 months and a psychiatric prescriber every 6-12 months 1.